(Q44131292)

30 November 2017

Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals (English)

1 reference

30 November 2017

1 reference

9

Jos H Beijnen

1 reference

30 November 2017

7

Eric C M Van Gorp

1 reference

30 November 2017

Monique M R De Maat

1

1 reference

30 November 2017

Ron A A Mathôt

2

1 reference

30 November 2017

Agnes I Veldkamp

3

1 reference

30 November 2017

Aldwin D R Huitma

4

1 reference

30 November 2017

Jan W Mulder

5

1 reference

30 November 2017

Pieter L Meenhorst

6

1 reference

30 November 2017

Hilde Carlier

8

1 reference

30 November 2017

1 September 2002

1 reference

30 November 2017

Pharmacological Research

1 reference

30 November 2017

46

1 reference

30 November 2017

3

1 reference

30 November 2017

295-300

1 reference

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

1 reference

7 January 2021

Lactic acidosis associated with stavudine administration: a report of five cases

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA)

1 reference

https://api.crossref.org/works/10.1016%2FS1043-6618%2802%2900146-9

7 January 2021

10.1016/S1043-6618(02)00146-9

Identifiers

DOI

1 reference

30 November 2017

1 reference